Sign up Australia
Proactive Investors - Run By Investors For Investors

Rhinomed looks to team up with largest medicinal cannabis operator in US

Rhinomed is a medical technology company with a patented nasal technology platform.
cannabis leaf near green pills and stethoscope
Rhinomed has launched two over-the-counter products in the Turbine® and the Mute®

Rhinomed Ltd (ASX:RNO) has signed a non-binding term sheet with Columbia Care LLC, the largest medical marijuana operator in the United States.

As per the term sheet, Rhinomed will license its nasal platform for the delivery of medical cannabis and cannabinoid products.

The two companies plan to jointly develop a range of unique cannabinoid products targeting areas with unmet clinical and consumer health needs in the US.

Progressing towards a binding agreement within 90 days

Rhinomed and Columbia Care are aiming to complete a binding agreement based on the term sheet within the next 90 days.

The agreement will deal with the licensing of Rhinomed’s platform technology, intellectual property, product royalties and supply of technology, exclusivity and other commercial issues.

Leveraging Rhinomed’s patented nasal technology

Rhinomed’s CEO Michael Johnson said: “We have steadfastly built a medical device platform that focuses on the role and importance of the nose.

“We have already built a significant global franchise as a leading consumer health brand in the global sleep market.

“In addition, our platform has obvious relevance across a range of other applications with nasal drug delivery being a key opportunity.

“We are delighted with the opportunity to partner with Columbia Care to bring a revolutionary range of nasally administered dose-controlled cannabis-based formats to the US market.

“By offering consumers and clinicians access to range of products that solve specific unmet clinical needs we firmly believe that we can modernise, and indeed, medicalise this market in a new and radical way.”

Medical technology company with two launched products

Rhinomed is a medical technology company with a patented nasal technology platform that seeks to improve the way people breathe, sleep, maintain their health and take medication.

Rhinomed has launched two over-the-counter technologies in the Turbine® and the Mute®.

The Turbine® is a nasal dilator designed to assist people in breathing easier during aerobic exercise.

The Mute® is a nasal technology that is designed to allow people to improve their sleep quality by breathing more and snoring less.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full RNO profile View Profile

Rhinomed Ltd Timeline

March 13 2017
September 16 2015

Related Articles

mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
June 21 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use